CAMBRIDGE, Mass., Sept. 28, 2016
CAMBRIDGE, Mass., Sept. 28, 2016 /PRNewswire/ -- EIP Pharma, LLC (www.eippharma.com) today announced that the U.S. Patent Office issued on August 30, 2016 the following two patents:
U.S. Patent No. 8,697,627, with claims directed towards administration of VX-745 to reduce brain amyloid plaque load, was issued to EIP Pharma in 2014. Patents with similar claims recently issued in Europe (EP 2707369) and in Japan (No. 5851022).
"These newly issued patents provide a strong proprietary position for VX-745 in each of Alzheimer's disease and Stroke recovery that will last well into the 2030s," said John Alam, MD, founder and CEO of EIP Pharma.
About VX-745 and p38 MAPK alpha
VX-745 is a brain-penetrant investigational drug that inhibits the intra-cellular enzyme p38 mitogen activated protein kinase alpha (MAPKa); and is currently in phase 2 clinical studies in patients with early Alzheimer's disease.
In the healthy brain, p38 MAPKa regulates inflammation through effects on immune cells. In conditions of stress and disease, p38 MAPKa is also expressed in neurons; where it plays a major role in inflammation and/or amyloid beta induced synaptic toxicity.
About EIP Pharma
EIP Pharma, LLC (www.eippharma.com) is a private R&D stage CNS-focused therapeutics company based in Cambridge, Massachusetts.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/eip-pharma-announces-issuance-of-multiple-new-patents-covering-vx-745-a-selective-p38-map-kinase-alpha-inhibitor-for-alzheimers-disease-and-ischemic-stroke-recovery-300335091.html
SOURCE EIP Pharma, LLCPR Newswire
Last updated on: 28/09/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.